Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
LYELthis companyLyell Immunopharma, Inc.	$16.35	-1.92×	2.12×	14,614.52×	-1.97×	-96.7%	-31952.8%	-566038.9%	-762355.6%	-110.6%	-68.0%	-28.7%	0.21×	0.03×	0×	5.28×	0.0%	1	-7.49	2	C+
ALDXAldeyra The	$0.67	-9.25×	7.03×	0×	-8.1×	55.2%	0.0%	0.0%	0.0%	-76.5%	-59.0%	-10.7%	0.35×	1.72×	-18.51×	2.58×	0.0%	2	-12.88	2	B-
ALLOAllogene Therapeutics, Inc.	$1.04	-1.57×	1.03×	0×	-1.88×	-114.2%	0.0%	0.0%	0.0%	-65.3%	-52.8%	-49.5%	0.28×	-0.18×	-192.5×	7.93×	0.0%	4	-3.65	2	C
CABACabaletta Bio, Inc.	$1.47	-1.34×	2×	0×	-1.02×	-65.7%	0.0%	0.0%	0.0%	-149.8%	-123.8%	-59.1%	0.24×	0.34×	-85.95×	2.77×	0.0%	2	-1.41	2	C+
EDITEditas Medicine, Inc.	$2.81	-1.14×	6.67×	4.49×	-0.75×	-308.6%	100.0%	-245.2%	-395.0%	-586.6%	-65.6%	-91.2%	2.81×	0.47×	-16.1×	3.54×	0.0%	3	-8.13	2	C
GNLXGenelux Corporation	$2.03	-5.07×	14.04×	20,261.21×	-5.02×	-100.6%	-7075.0%	-415175.0%	-401812.5%	-278.5%	-251.1%	-16.3%	0.15×	0.12×	0×	2.43×	0.0%	2	-14.59	1	C-
Peer median	—	-1.57×	6.67×	0×	-1.88×	-100.6%	0.0%	0.0%	0.0%	-149.8%	-65.6%	-49.5%	0.28×	0.34×	-18.51×	2.77×	0.0%	2	-8.13	2	—